A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

NCT02975349 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

267

Enrollment

INDUSTRY

Sponsor class

Stopped Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies.

Conditions

Relapsing-remitting Multiple Sclerosis

Interventions

DRUG: Evobrutinib
DRUG: Evobrutinib
DRUG: Evobrutinib
DRUG: Placebo
DRUG: Tecfidera

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]